Moleculin Biotech Stock Return On Equity

MBRX Stock  USD 5.54  0.86  18.38%   
Moleculin Biotech fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.
Return On Equity is likely to drop to -1.2 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Moleculin Return On Equity Analysis

Moleculin Biotech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Moleculin Biotech Return On Equity

(1.2)

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Moleculin Biotech Return On Equity

    
  -0.76  
Most of Moleculin Biotech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Moleculin Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as Return On Equity. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
0.430.990.8-0.98-0.750.690.920.56-0.740.98-0.790.550.330.840.710.250.680.890.93-0.120.12-0.23
0.430.370.66-0.36-0.710.210.530.58-0.60.35-0.510.420.230.510.670.810.490.230.280.620.06-0.8
0.990.370.78-0.99-0.680.640.880.43-0.670.99-0.710.440.210.760.680.170.570.930.95-0.10.01-0.18
0.80.660.78-0.79-0.940.710.890.52-0.580.79-0.660.350.140.740.970.70.530.740.760.38-0.1-0.68
-0.98-0.36-0.99-0.790.69-0.62-0.88-0.430.58-1.00.7-0.42-0.21-0.77-0.68-0.2-0.57-0.96-0.980.08-0.020.19
-0.75-0.71-0.68-0.940.69-0.78-0.9-0.760.7-0.70.79-0.6-0.42-0.86-0.94-0.75-0.74-0.56-0.62-0.25-0.180.71
0.690.210.640.71-0.62-0.780.820.6-0.640.64-0.730.510.330.770.770.330.670.50.54-0.170.11-0.26
0.920.530.880.89-0.88-0.90.820.72-0.750.89-0.840.590.360.940.840.510.750.750.810.00.16-0.36
0.560.580.430.52-0.43-0.760.60.72-0.750.46-0.860.90.80.880.530.550.930.190.31-0.150.66-0.39
-0.74-0.6-0.67-0.580.580.7-0.64-0.75-0.75-0.60.8-0.74-0.51-0.76-0.6-0.38-0.75-0.37-0.440.07-0.320.33
0.980.350.990.79-1.0-0.70.640.890.46-0.6-0.720.440.240.790.680.20.590.950.98-0.10.05-0.19
-0.79-0.51-0.71-0.660.70.79-0.73-0.84-0.860.8-0.72-0.8-0.67-0.89-0.64-0.39-0.94-0.51-0.60.19-0.440.33
0.550.420.440.35-0.42-0.60.510.590.9-0.740.44-0.80.940.80.330.230.920.190.31-0.420.83-0.22
0.330.230.210.14-0.21-0.420.330.360.8-0.510.24-0.670.940.610.110.110.820.010.14-0.510.93-0.17
0.840.510.760.74-0.77-0.860.770.940.88-0.760.79-0.890.80.610.70.460.890.590.68-0.170.46-0.3
0.710.670.680.97-0.68-0.940.770.840.53-0.60.68-0.640.330.110.70.730.530.610.630.43-0.15-0.72
0.250.810.170.7-0.2-0.750.330.510.55-0.380.2-0.390.230.110.460.730.340.10.140.71-0.03-0.85
0.680.490.570.53-0.57-0.740.670.750.93-0.750.59-0.940.920.820.890.530.340.360.46-0.30.63-0.29
0.890.230.930.74-0.96-0.560.50.750.19-0.370.95-0.510.190.010.590.610.10.360.99-0.02-0.16-0.15
0.930.280.950.76-0.98-0.620.540.810.31-0.440.98-0.60.310.140.680.630.140.460.99-0.07-0.04-0.17
-0.120.62-0.10.380.08-0.25-0.170.0-0.150.07-0.10.19-0.42-0.51-0.170.430.71-0.3-0.02-0.07-0.6-0.7
0.120.060.01-0.1-0.02-0.180.110.160.66-0.320.05-0.440.830.930.46-0.15-0.030.63-0.16-0.04-0.60.05
-0.23-0.8-0.18-0.680.190.71-0.26-0.36-0.390.33-0.190.33-0.22-0.17-0.3-0.72-0.85-0.29-0.15-0.17-0.70.05
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Moleculin Total Stockholder Equity

Total Stockholder Equity

28.87 Million

At this time, Moleculin Biotech's Total Stockholder Equity is fairly stable compared to the past year.
Based on the latest financial disclosure, Moleculin Biotech has a Return On Equity of -0.7607. This is 96.83% lower than that of the Biotechnology sector and 97.91% lower than that of the Health Care industry. The return on equity for all United States stocks is 145.39% higher than that of the company.

Moleculin Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.
Moleculin Biotech is currently under evaluation in return on equity category among related companies.

Moleculin Fundamentals

About Moleculin Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Return On Equity(1.14)(1.20)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Moleculin Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moleculin Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moleculin Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moleculin Biotech Stock:
Check out Moleculin Biotech Piotroski F Score and Moleculin Biotech Altman Z Score analysis.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(15.15)
Return On Assets
(0.39)
Return On Equity
(0.76)
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.